|
|
| |
| Pharmaceuticals \ EMLA |
EMLA Product Brief
| TOPICAL SKIN ANALGESIC RECEIVES U.S. MARKETING AUTHORIZATION
Astra Pharmaceutical Products, Inc., Westborough, Mass., announced that EMLA Cream (lidocaine 2.5% and prilocaine 2.5%) received U.S. government approval. EMLA Cream is a unique local skin anesthetic that can eliminate the need for needle injection during many dermal procedures in patients from 1 month of age through adulthood.
EMLA combines the Astra-developed anesthetics lidocaine and prilocaine in an oil-and-water emulsion that allows high concentrations of the pain killers to reach nerve endings in the dermis directly through the intact epidermal layers of skin. Instead of a needle, EMLA Cream is applied under an occlusive dressing for 60 minutes, anesthetizing the skin for a period of 60 minutes to 120 minutes after the dressing is removed. In some patients, temporary blanching or redness or the skin appears, however, this normally resolves itself after a few hours.
Cosmetic Dermatology, March 1993, New Product Briefs, p. 64
|
|
|
|
|
|
|
|
